San Diego, October 11, 2021 (GLOBE NEWSWIRE) – via NewMediaWire – Medical Marijuana, Inc. (OTC: MJNA) (the “Company”), the first publicly traded cannabis company in the United States to launch the world’s first cannabis-derived products, brands and supply chain, today announced that the Japanese division of the company’s subsidiary Kannawi® The month saw the largest revenue in the division’s history for September 2021. The medical marijuana subsidiary’s manufacturing subsidiary also saw the largest monthly revenue in the division’s history last month.
“When asked about our company’s greatest opportunity, I always share that we aim to be the first truly global cannabis company, introducing cannabis-based products to global emerging markets, and Japan’s success is the perfect illustration of that vision indeed,” said Medical Marijuana CEO Blake Schroeder. The Asian market represents one of the biggest growth opportunities for cannabis products. It is relatively untapped and our entry just over two years ago has easily given us a first mover advantage. Our products have been exceptionally well received in the market and I look forward to continued expansion in the region.”
“Outside of Japan, we recently announced our entry into Hong Kong, where a population of about 7.5 million people has historically had minimal access to cannabis-based products. We have successfully gained the same first mover advantage as we did in Japan and I am excited to see the results of this Expand the market in the coming weeks and months. We are truly a company of firsts, being first in the markets, first in product innovation and development, and first in terms of product quality,” added Schroeder.
According to Research and Markets, the global CBD oil market is expected to reach $5.3 billion by 2025 With Asia Pacific as one of the fastest growing regions.
About Medical Marijuana, Inc.
We are Firsts® شركة. Medical Marijuana, Inc. (MJNA) is a cannabis company with three distinct business units in the non-psychoactive cannabis space: a global group of cannabis-based food brands led by Kannawi® And HempMeds®; A leader in sourcing high-quality legal, non-psychoactive cannabis products derived from industrial hemp; and the sector of cannabis-based clinical research and development of botanical medicines led by pharmaceutical investment companies and their partners including AXIM® Biotechnologies, Inc. And Neuropathics. Medical Marijuana, Inc. was selected. As the best CBD product ever CNBC. Medical Marijuana, Inc. Also the first company to obtain historic import permits for CBD products from the governments of Brazil, Mexico, Argentina and Paraguay and is a pioneer in developing international markets. The company’s main product Real scientific hemp oil It has been used in several successful clinical studies throughout Mexico and Brazil to understand its safety and efficacy.
Medical Marijuana, Inc. is headquartered in In San Diego, California, additional information is available at OTCMarkets.com or by visiting www.medicalmarijuanainc.com. To watch a video of Medical Marijuana, Inc. , click here.
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Exchange Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the safe harbor law created by those sections. This material contains statements about expected future events and/or financial results of a forward-looking nature and subject to risks and uncertainties. These forward-looking statements by definition include risks, uncertainties and other factors, which could cause Medical Marijuana, Inc.’s actual results, performance or achievements to differ. materially from the data contained herein.
Disclosure by the Food and Drug Administration (FDA)
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Medical Marijuana, Inc. does not. Selling or distributing any products that violate the Controlled Substances Act in the United States.
Public Relations Contact:
Investor Relations Contact:
p. (858) 283-4016